



## **BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023**

July 24, 2023

**MAINZ, Germany, July 24, 2023 (GLOBE NEWSWIRE)** – [BioNTech SE](#) (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2023 on Monday, August 7<sup>th</sup>, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2023.

To access the live conference call via telephone, please register via this [link](#). Once registered, dial-in numbers and a pin will be provided. It is recommended to register at least a day in advance.

The slide presentation and audio of the webcast will be available via this [link](#).

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at [www.BioNTech.com](#). A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

### **About BioNTech**

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Regeneron, Sanofi, and Pfizer.

For more information, please visit [www.BioNTech.com](#).

### **BioNTech Contacts**

#### **Investor Relations**

Victoria Meissner, M.D.  
+1 617 528 8293  
[Investors@biontech.de](mailto:Investors@biontech.de)

#### **Media Relations**

Jasmina Alatovic  
+49 (0)6131 9084 1513  
[Media@biontech.de](mailto:Media@biontech.de)